Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors

Drugs of Today

Volumn 49, Issue 2, 2013, Pages 89-103

  Feelders, R A ^a   De Herder, W W ^a   Neggers, S J ^a   Van Der Lely, A J ^a   Hofland, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cushing's disease; Growth hormone release inhibitors; Pasireotide; SoM 230

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; GLUCAGON; KETOCONAZOLE; OCTREOTIDE; PASIREOTIDE; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TEMOZOLOMIDE;

ABDOMINAL PAIN; ACROMEGALY; ANGIOGENESIS; ARTICLE; CALCIUM CELL LEVEL; CARDIOVASCULAR MORTALITY; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CUSHING DISEASE; CUSHING SYNDROME; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FLATULENCE; GALLSTONE; GASTRINOMA; GASTROINTESTINAL SYMPTOM; GLUCAGONOMA; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; IN VITRO STUDY; INSULINOMA; METABOLIC SYNDROME X; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PROLACTINOMA; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOMATOSTATINOMA; TREATMENT DURATION; TUMOR GROWTH;

CUSHING'S DISEASE; GROWTH HORMONE RELEASE INHIBITORS; PASIREOTIDE; SOM-230;

ACROMEGALY; HUMANS; LIGANDS; NEUROENDOCRINE TUMORS; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84874738532     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.2.1915142     Document Type: Article

References (85)

1. Patel, Y.C. Somatostatin and its receptor family. Front neuroendocrinol 1999, 20(3): 157-98.
2. De Martino, M.C., Hofland, L.J., Lamberts, S.W. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. prog Brain res 2010, 182: 255-80.
3. Feelders, R.A., Hofland, L.J., van aken, M.O., Neggers, S.J., Lamberts, S.W., de Herder, W.W., van der Lely, A.J. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 2009, 69(16): 2207-26.
4. Modlin, I.M., oberg, K., Chung, D.C. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet oncol 2008, 9(1): 61-72.
5. van der Hoek, J., Waaijers, M., van Koetsveld, P.M. et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. am J physiol Endocrinol Metab 2005, 289(2): E278-87.
6. Schmid, H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008, 286(1-2): 69-74.
7. Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., rivier, J., guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179(4068): 77-9.
8. panetta, R., Patel, Y.C. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1995, 56(5): 333-42.
9. Miller, G.M., alexander, J.M., Bikkal, H.A., Katznelson, L., Zervas, N.T., Klibanski, A. Somatostatin receptor subtype gene expression in pituitary adenomas. J CliN Endocrinol Metab 1995, 80(4): 1386-92.
10. Florio, T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008, 13: 822-40.
11. Shimon, I., Taylor, J.E., Dong, J.Z. et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulatioN. J Clin Invest 1997, 99(4): 789-98.
12. Hofland, L.J. Somatostatin and somatostatin receptors in Cushing's disease.Mol Cell Endocrinol 2008, 286(1-2): 199- 205.
13. rocheville, M., Lange, D.C., Kumar, U., Patel, S.C., Patel, R.C., Patel, Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288(5463): 154-7.
14. Ben-Shlomo, A., Zhou, C., pichurin, O., Chesnokova V., Liu, N.A., Culler, M.D., Melmed, S. Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol 2009, 23(3): 337-48.
15. Melmed, S. Medical progress: Acromegaly. N Engl J Med 2006, 355(24): 2558-73.
16. Sherlock, M., ayuk, J., Tomlinson, J.W. et al. Mortality in patients with pituitary disease. Endocr rev 2010, 31(3): 301-42.
17. Freda, P.U. Somatostatin analogs in acromegaly. J CliN Endocrinol Metab 2002, 87(7): 3013-8.
18. neggers, S.J., van der Lely, A.J. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. growth horm IgF res 2011, 21(3): 129-33.
19. van der Hoek, J., de herder, W.W., Feelders, R.A. et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J CliN Endocrinol Metab 2004, 89(2): 638-45.
20. Matrone, C., pivonello, R., Colao, A. et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. neuroendocrinology 2004, 79(3): 142-8.
21. Thodou, E., Kontogeorgos, G., Theodossiou, D., pateraki, M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin pathol 2006, 59(3): 274-9.
22. newell-price, J., Bertagna, X., grossman, A.B., nieman, L.K. Cushing's syndrome. Lancet 2006, 367(9522): 1605-17.
23. Feelders, R.A., pulgar, S.J., Kempel, A., pereira, A.M. Management of endocrine disease: The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012, 167(3): 311-26.
24. Biller, B.M., grossman, A.B., Stewart, P.M. et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J CliN Endocrinol Metab 2008, 93(7): 2454-62.
25. Patil, C.G., Prevedello, D.M., Lad, S.P., Vance, M.L., Thorner, M.O., Katznelson, L., Laws, E.R., JR. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J CliN Endocrinol Metab 2008, 93(2): 358-62.
26. Feelders, R.A., Hofland, L.J., de herder, W.W. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. neuroendocrinology 2010, 92(Suppl. 1): 111-5.
27. van der pas, R., de herder, W.W., Hofland, L., Feelders, R.A. New developments in medical therapy of Cushing's syndrome. Endocr relat Cancer 2012, 19(6): r205-23.
28. de Bruin, C., pereira, A.M., Feelders, R.A. et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J CliN Endocrinol Metab 2009, 94(4): 1118-24.
29. Dekkers, O.M., Biermasz, N.R., pereira, A.M., roelfsema, F., van aken, M.O., Voormolen, J.H., romijn, J.A. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenomA. J CliN Endocrinol Metab 2007, 92(3): 976-81.
30. Klibanski, A. Clinical practice. Prolactinomas. N Engl J Med 2010, 362(13): 1219-26.
31. Jaquet, P., ouafik, L., Saveanu, A. et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J CliN Endocrinol Metab 1999, 84(9): 3268-76.
32. Whitelaw, B.C., Dworakowska, D., Thomas, N.W. et al. Temozolomide in the management of dopamine agonistresistant prolactinomas. CliN Endocrinol (oxf) 2012, 76(6): 877-86.
33. rindi, G., Bordi, C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr relat Cancer 2003, 10(4): 427-36.
34. Yao, J.C., hassan, M., phan, A. et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin oncol 2008, 26(18): 3063-72.
35. van der Lely, A.J., de herder, W.W. Carcinoid syndrome: diagnosis and medical management. arq Bras Endocrinol Metabol 2005, 49(5): 850-60.
36. Volante, M., rosas, R., allia, E., granata, R., Baragli, A., Muccioli, G., papotti, M. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol 2008, 286(1-2): 219-29.
37. Lamberts, S.W., de herder, W.W., Hofland, L.J. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002, 13(10): 451-7.
38. Hofland, L.J., Lamberts, S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr rev 2003, 24(1): 28-47.
39. Kulaksiz, H., Eissele, R., rossler, D., Schulz, S., hollt, V., Cetin, Y., arnold, R. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. gut 2002, 50(1): 52-60.
40. Kwekkeboom, D.J., Kam, B.L., vaN Essen, M. et al. Somatostatin-receptor- based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr relat Cancer 2010, 17(1): r53-73.
41. de herder, W.W., Lamberts, S.W. Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. Endocrine 2003, 20(3): 285-90.
42. rinke, A., Muller, H.H., Schade-Brittinger, C. et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GrouP. J Clin oncol 2009, 27(28): 4656-63.
43. Kwekkeboom, D.J., de herder, W.W., Kam, B.L. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin oncol 2008, 26(13): 2124-30.
44. Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., Weckbecker, G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146(5): 707-16.
45. Ma, P., Wang, Y., van der Hoek, J., nedelman, J., Schran, H., Tran, L.L., Lamberts, S.W. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin pharmacol Ther 2005, 78(1): 69-80.
46. Feelders, R.A., Yasothan, U., Kirkpatrick, P. Pasireotide. nat rev Drug Discov 2012, 11(8): 597-8.
47. Golor, G., hu, K., ruffin, M., Buchelt, A., Bouillaud, E., Wang, Y., Maldonado, M. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 2012, 6: 71-9.
48. petersenn, S., hu, K., Maldonado, M. et al. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study. Clin Ther 2012, 34(3): 677-88.
49. petersenn, S., Unger, N., hu, K. et al. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J Clin pharmacol 2012, 52(7): 1017-27.
50. Weckbecker, G., Briner, U., Lewis, I., Bruns, C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002, 143(10): 4123-30.
51. Hofland, L.J., van der Hoek, J., van Koetsveld, P.M. et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitrO. J CliN Endocrinol Metab 2004, 89(4): 1577-85.
52. petersenn, S., Schopohl, J., Barkan, A. et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J CliN Endocrinol Metab 2010, 95(6): 2781-9.
53. Hofland, L.J., van der Hoek, J., Feelders, R. et al. The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005, 152(4): 645-54.
54. Batista, D.L., Zhang, X., Gejman, R. et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J CliN Endocrinol Metab 2006, 91(11): 4482-8.
55. Silva, A.P., Schoeffter, P., Weckbecker, G., Bruns, C., Schmid, H.A. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 2005, 153(3): r7-r10.
56. Boscaro, M., Ludlam, W.H., atkinson, B. et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J CliN Endocrinol Metab 2009, 94(1): 115-22.
57. Colao, A., petersenn, S., newell-price, J. et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012, 366(10): 914-24.
58. Feelders, R.A., de Bruin, C., pereira, A.M. et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010, 362(19): 1846-8.
59. Feelders, R.A., Hofland L.J. Medical treatment of Cushing's disease. J CliN Endocrinol and Metab 2013, 98(2): 425-38.
60. van Hoek, M., Hofland, L.J., de rijke, Y.B. et al. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. J CliN Endocrinol Metab 2009, 94(2): 428-33.
61. ono, K., Suzuki, T., Miki, Y. et al. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. anticancer res 2007, 27(4B): 2231-9.
62. Kidd, M., Drozdov, I., Joseph, R., pfragner, R., Culler, M., Modlin, I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008, 113(4): 690-700.
63. Zatelli, M.C., Minoia, M., Martini, C. et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr relat Cancer 2010, 17(3): 719-29.
64. Quinn, T.J., Yuan, Z., adem, A. et al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery 2012, 152(6): 1068-77.
65. Schmid, H.A., Silva, A.P. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest 2005, 28(11 Suppl. Intl.): 28-35.
66. Lesche, S., Lehmann, D., nagel, F., Schmid, H.A., Schulz, S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitrO. J CliN Endocrinol Metab 2009, 94(2): 654-61.
67. Kvols, L.K., oberg, K.E., o'Dorisio, T.M. et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr relat Cancer 2012, 19(5): 657-66.
68. Yao, J.C., Shah, M.h., Ito, T. et al. Everolimusfor advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6): 514-23.
69. pavel, M.E., hainsworth, J.D., Baudin, E. et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378(9808): 2005-12.
70. Chan, J.A., ryan, D.P., Zhu, A.X. et al. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr relat Cancer 2012, 19(5): 615-23.
71. Beck-peccoz, P., persani, L., Mannavola, D., Campi, I. Pituitary tumours: TSH-secreting adenomas. Best pract res CliN Endocrinol Metab 2009, 23(5): 597-606.
72. gatto, F., Barbieri, F., gatti, M. et al. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. CliN Endocrinol (oxf) 2012, 76(3): 407-14.
73. Hofland, L.J., Lamberts, S.W. Somatostatin receptors in pituitary function, diagnosis and therapy. Front horm res 2004, 32: 235-52.
74. Colao, A., Di Somma, C., pivonello, R., Faggiano, A., Lombardi, G., Savastano, S. Medical therapy for clinically non-functioning pituitary adenomas. Endocr relat Cancer 2008, 15(4): 905-15.
75. Zatelli, M.C., piccin, D., Vignali, C. et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretioN. Endocr relat Cancer 2007, 14(1): 91-102.
76. Eisenhofer, G., Siegert, G., Kotzerke, J., Bornstein, S.R., pacak, K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. horm Metab res 2008, 40(5): 329-37.
77. Hofland, L.J., Liu, Q., Van Koetsveld, P.M. et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J CliN Endocrinol Metab 1999, 84(2): 775-80.
78. Saveanu, A., Muresan, M., De Micco, C. et al. Expression of somatostatin receptors, dopamine D(2) receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. Endocr relat Cancer 2011, 18(2): 287-300.
79. Lamarre-Cliche, M., gimenez-roqueplo, A.P., Billaud, E., Baudin, E., Luton, J.P., plouin, P.F. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytomA. CliN Endocrinol (oxf) 2002, 57(5): 629-34.
80. Pasquali, D., Rossi, V., Conzo, G. et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008, 40(6): 263-71.
81. hasskarl, J., Kaufmann, M., Schmid, H.A. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future oncol 2011, 7(7): 895-913.
82. Kokona, D., Mastrodimou, N., pediaditakis, I., Charalampopoulos, I., Schmid, H.A., Thermos, K. Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies. Exp Eye res 2012, 103: 90-8.
83. Shenouda, M., Maldonado, M., Wang, Y., Bouillaud, E., hudson, M., nesheiwat, D., hu, K. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: Safety, tolerability, and effects on glucose, insulin, and glucagon levels. am J Ther 2012, advance publicatioN.
84. henry r, M.S., Wetli-hermosillo K, Ligueros-Saylan M, Chenji S and Golor g, Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. 93rd annu Meet Endo Soc (June 4-7, Boston) 2011, abst p3-274.
85. Schmid, H.A., Brueggen, J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 2012, 212(1): 49-60.